Claims
- 1. A method for treating a human patient suffering from a hereditary condition comprising administering to the patient a therapeutically effective amount of a TNFα inhibitor, wherein the hereditary condition is selected from the group consisting of Gaucher's disease, Huntington's disease, linear IgA disease, and muscular dystrophy.
- 2. The method of claim 1, wherein the hereditary condition is linear IgA disease.
- 3. The method of claim 2, wherein the TNFα inhibitor is TNFR:Fc.
- 4. The method of claim 3, wherein the TNFR:Fc is administered by subcutaneous injection.
- 5. The method of claim 3, wherein the TNFR:Fc is administered at least about once a week.
- 6. The method of claim 3, wherein a single dose of TNFR:Fc contains from 5 milligrams to 100 milligrams of TNFR:Fc.
- 7. The method of claim 6, wherein a single dose of TNFR:Fc contains about 25 milligrams of TNFR:Fc.
- 8. The method of claim 6, wherein a single dose of TNFR:Fc contains about 50 milligrams of TNFR:Fc.
- 9. The method of claim 2, wherein the TNFα inhibitor is an antibody that binds to TNFα.
- 10. The method of claim 9, wherein the antibody is administered by subcutaneous injection.
- 11. The method of claim 8, wherein the antibody is administered by infusion.
- 12. The method of claim 2, wherein the TNFα inhibitor is administered concurrently with a drug selected from the group consisting of: azathioprine, cyclophosphamide, cyclosporine, hydroxychloroquine sulfate, methotrexate, leflunomide, minocycline, penicillamine, sulfasalazine and gold compounds such as oral gold, gold sodium thiomalate, and aurothioglucose.
- 13. The method of claim 12, wherein the TNFα inhibitor is administered concurrently with methotrexate.
- 14. A method for treating a human patient suffering from a neurological condition comprising administering to the patient a therapeutically effective amount of a TNFα inhibitor, wherein the neurological condition is selected from the group consisting of Guillain-Barre syndrome, Parkinson's disease, and Bell's palsy.
- 15. The method of claim 14, wherein the TNFα inhibitor is TNFR:Fc.
- 16. The method of claim 15, wherein a single dose of TNFR:Fc contains from 5 milligrams to 100 milligrams of TNFR:Fc.
- 17. The method of claim 14, wherein the TNFα inhibitor is a human or humanized antibody against TNFα.
- 18. A method for treating a human patient suffering from adult respiratory distress syndrome comprising administering to said patient a therapeutically effective amount of a soluble TNF receptor.
- 19. The method of claim 18, wherein the soluble TNF receptor is TNFR:Fc.
- 20. A method for treating a human patient suffering from renal failure comprising administering to said patient a therapeutically effective amount of a soluble TNF receptor.
- 21. The method of claim 20, wherein the soluble TNF receptor comprises an extracellular region of p55.
- 22. A method for treating gout in a human patient comprising administering to said patient a therapeutically effective amount of a TNFα inhibitor.
- 23. The method of claim 22, wherein the TNFα inhibitor is TNFR:Fc.
- 24. The method of claim 22, wherein the TNFα inhibitor is a human or humanized antibody that binds to TNFα.
Parent Case Info
[0001] This application is a divisional of U.S. application Ser. No. 09/602,351, filed Jun. 23, 2000, now pending, which claims benefit of U.S. Provisional Application Nos. 60/164,676, filed Nov. 10, 1999, now abandoned, and 60/184,864, filed Feb. 25, 2000, now abandoned, and which is a continuation-in-part of U.S. application Ser. No. 09/373,828, filed Aug. 13, 1999, now abandoned, which claims the benefit of U.S. Provisional Application Nos. 60/130,074, filed Apr. 19, 1999, now abandoned, 60/134,320, filed May 14, 1999, now abandoned, 60/143,959, filed Jul. 15, 1999, now abandoned, and 60/148,234, filed Aug. 11, 1999, now abandoned, all of which are incorporated herein by reference in their entirety.
Provisional Applications (6)
|
Number |
Date |
Country |
|
60164676 |
Nov 1999 |
US |
|
60184864 |
Feb 2000 |
US |
|
60130074 |
Apr 1999 |
US |
|
60134320 |
May 1999 |
US |
|
60143959 |
Jul 1999 |
US |
|
60148234 |
Aug 1999 |
US |
Divisions (1)
|
Number |
Date |
Country |
Parent |
09602351 |
Jun 2000 |
US |
Child |
10853479 |
May 2004 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
09373828 |
Aug 1999 |
US |
Child |
10853479 |
May 2004 |
US |